Clinical Trial Update: Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of gemcitabine and bexarotene for progressive or refractory cutaneous T-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Bexarotene (Bexarotene)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: University College, London | Conditions: Lymphoma | Phase 2 | Status: COMPLETED